ATE529419T1 - Chromanderivate als estrogene verbindungen - Google Patents

Chromanderivate als estrogene verbindungen

Info

Publication number
ATE529419T1
ATE529419T1 AT01929361T AT01929361T ATE529419T1 AT E529419 T1 ATE529419 T1 AT E529419T1 AT 01929361 T AT01929361 T AT 01929361T AT 01929361 T AT01929361 T AT 01929361T AT E529419 T1 ATE529419 T1 AT E529419T1
Authority
AT
Austria
Prior art keywords
chromeder
derivatives
estrogenic compounds
estrogenic
compounds
Prior art date
Application number
AT01929361T
Other languages
English (en)
Inventor
Gerrit Veeneman
Neeltje Teerhuis
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Application granted granted Critical
Publication of ATE529419T1 publication Critical patent/ATE529419T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
AT01929361T 2000-03-01 2001-02-26 Chromanderivate als estrogene verbindungen ATE529419T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00200713 2000-03-01
PCT/EP2001/002144 WO2001064665A1 (en) 2000-03-01 2001-02-26 Chroman derivatives as estrogenic compounds

Publications (1)

Publication Number Publication Date
ATE529419T1 true ATE529419T1 (de) 2011-11-15

Family

ID=8171123

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01929361T ATE529419T1 (de) 2000-03-01 2001-02-26 Chromanderivate als estrogene verbindungen

Country Status (9)

Country Link
US (3) US7214706B2 (de)
EP (1) EP1282615B1 (de)
JP (1) JP4896335B2 (de)
AR (1) AR027571A1 (de)
AT (1) ATE529419T1 (de)
AU (1) AU2001256164A1 (de)
CO (1) CO5261596A1 (de)
PE (1) PE20011077A1 (de)
WO (1) WO2001064665A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1448544T1 (sl) * 2001-11-19 2007-10-31 Lilly Co Eli Substituirani benzopirani kot selektivni agonistiestrogenskega receptorja beta
CA2467013C (en) * 2001-11-19 2010-08-10 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US6630508B1 (en) 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists
AU2003212856A1 (en) * 2002-03-01 2003-09-16 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
PL1626974T3 (pl) 2003-04-21 2009-01-30 Lilly Co Eli Podstawione benzopirany jako selektywne związki agonistyczne receptora beta estrogenu
DE602004025460D1 (de) * 2003-04-21 2010-03-25 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
CA2578164A1 (en) 2004-09-07 2006-03-16 Wyeth 6h-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents
ES2361031T3 (es) 2004-10-18 2011-06-13 Eli Lilly And Company Benzopiranos sustituidos como agonistas selectivos del receptor beta de estrógenos.
CN101641013B (zh) 2007-01-22 2014-07-30 Gtx公司 核受体结合剂
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US8063102B2 (en) 2009-03-13 2011-11-22 N.V. Organon Tetrahydronaphthalen-2-ol derivatives
TW201043595A (en) * 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
US11511035B2 (en) 2016-07-28 2022-11-29 Cerebral Therapeutics, Inc. Implantable intraventricular sampling and infusion access device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) * 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
DE1543749A1 (de) * 1966-02-16 1969-12-11 Merck Ag E Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5280040A (en) 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
HUP9702244A3 (en) * 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders
CA2200423C (en) 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
EP0937057B1 (de) 1996-10-28 2003-01-15 Novo Nordisk A/S (-)-enantiomere von cis-3,4-chromanderivaten zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
CO5261596A1 (es) 2003-03-31
US20060160889A1 (en) 2006-07-20
EP1282615A1 (de) 2003-02-12
US20090221695A1 (en) 2009-09-03
JP2003525285A (ja) 2003-08-26
US7531571B2 (en) 2009-05-12
PE20011077A1 (es) 2001-12-12
JP4896335B2 (ja) 2012-03-14
WO2001064665A1 (en) 2001-09-07
EP1282615B1 (de) 2011-10-19
US7214706B2 (en) 2007-05-08
AU2001256164A1 (en) 2001-09-12
US20030069303A1 (en) 2003-04-10
US7846966B2 (en) 2010-12-07
AR027571A1 (es) 2003-04-02

Similar Documents

Publication Publication Date Title
ATE299875T1 (de) Benzoamid-piperidin verbindungen als substanz p- antagonisten
ATE368658T1 (de) Hetorocyclindazole und -azaindazole verbindungen als 5-hydroxytryptamine-6 liganden
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
DE60031481D1 (de) Polymer-gebundene funktionelle Verbindungen
NO20026253L (no) Organiske forbindelser
DE60111734D1 (de) [1,4']-bipiperidin verbindungen
ATE407672T1 (de) Glukokinase beeinflussende verbindungen
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
DE60134094D1 (de) C7-taxanester als antitumormittel
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
ATE529419T1 (de) Chromanderivate als estrogene verbindungen
DE60137061D1 (de) Platin-verbindungen als antitumorwirkstoffe
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
PT1299356E (pt) Novos compostos
ATE372338T1 (de) Deshalogenverbindungen
AR028220A1 (es) Novedosos compuestos
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
NO20030303L (no) Kalsilytiske forbindelser
NO20023508D0 (no) Kalsilyttiske forbindelser
NO20031837D0 (no) Kalsilytiske forbindelser
DE60106606D1 (de) Substituierte stilbenverbindungen als glucoseaufnahme inhibitoren
AR028399A1 (es) Nuevos compuestos
SE0003477D0 (sv) Compounds
AR027949A1 (es) Novedosos compuestos
IS8574A (is) Ný efnasambönd

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties